

*This report contains the collective views of an International group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.*

# **The use of essential drugs**

---

Report of a  
WHO Expert Committee

World Health Organization  
Technical Report Series  
685

---



World Health Organization, Geneva 1983

Reprinted 1983  
(incorporating corrigenda)

ISBN 92 4 120685 3

© World Health Organization 1983

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. For rights of reproduction or translation of WHO publications, in part or *in toto*, application should be made to the Office of Publications, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

83/5660 - Schüler S.A. - 8500  
83/5825 - Schüler S.A. - 12 000 (R)

## CONTENTS

	Page
1. Introduction .....	7
2. Guidelines for establishing a national programme for essential drugs.....	8
3. Criteria for the selection of essential drugs.....	9
4. Guidelines for the selection of pharmaceutical dosage forms.....	10
5. Updating of lists of essential drugs.....	11
6. Provision of information on essential drugs.....	11
7. Quality assurance.....	12
8. Research and development.....	13
9. Specialized applications of the essential-drugs concept.....	14
10. Revised model list of essential drugs .....	14
11. Changes made in revising the model list.....	39
12. Essential drugs and primary health care.....	42
12.1 Factors affecting the selection of essential drugs for primary health care.....	42
12.2 A model list of drugs for primary health care.....	43
12.3 Training material .....	44
13. Glossary of terms used in the report.....	44

## WHO EXPERT COMMITTEE ON THE USE OF ESSENTIAL DRUGS

Geneva, 29 November–3 December 1982

### *Members*

- Professor D. Azarnoff, President, Searle Research and Development, Division of G.D. Searle & Co, Chicago, IL, USA
- Dr I. Darmansjah, Head, Department of Pharmacology, University of Indonesia Medical School, and Chairman, Drug Evaluation Committee, Department of Health of Indonesia, Jakarta, Indonesia
- Professor A.W. El Borolossy, Vice-President for Medical Affairs, University of Jordan, Amman, Jordan
- Professor D.R. Laurence, Department of Clinical Pharmacology, University College Medical School, University of London, London, England (*Vice-Chairman*)
- Professor V.K. Lepahin, First Vice-President of the Pharmacological Committee and Head of the Department of Control of Drugs, Ministry of Health of the USSR, Moscow, USSR
- Dr Li Jia-tai, Deputy Director, Institute of Clinical Pharmacology and Director of the Department of Antibiotics, First Teaching Hospital, Beijing Medical College, Beijing, China
- Professor L.A. Salako, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria (*Rapporteur*)
- Professor U.K. Sheth, Former Director of Pharmacology, Seth G.S. Medical College, Bombay, India (*Chairman*)
- Professor A.C. Zanini, Secretary, National Health Surveillance Secretariat, Ministry of Health, Brasilia, Brazil (*Rapporteur*)

### *Representatives of other organizations*

#### *United Nations Children's Fund*

- Dr H. Probst, Senior Procurement Officer, UNICEF Office for Europe, Geneva, Switzerland
- Mr P. Heslop, Project Adviser, Joint WHO/UNICEF Programme on Essential Drugs, UNICEF, New York, NY, USA

#### *Council for International Organizations of Medical Sciences*

- Dr Z. Bankowski, Executive Secretary, Council for International Organizations of Medical Sciences, Geneva, Switzerland

#### *International Federation of Pharmaceutical Manufacturers Associations*

- Mr S.M. Peretz, Executive Vice-President, International Federation of Pharmaceutical Manufacturers Associations, Zürich, Switzerland

#### *International Pharmaceutical Federation*

- Professor F.W.H.M. Merkus, International Pharmaceutical Federation, Department of Biopharmaceutics, Faculty of Medicine and Pharmacy, University of Amsterdam, Amsterdam, Netherlands

*International Union of Pharmacology*

Professor P.G. Waser, IUPHAR Liaison Officer with WHO, University  
Pharmacological Institute, Zürich, Switzerland

*World Federation of Proprietary Medicine Manufacturers*

Dr K. Reese, Director-General, World Federation of Proprietary Medicine  
Manufacturers, Cologne, Federal Republic of Germany

*Secretariat*

Professor M.M.S. Ahuja, Head, Department of Medicine, All-India Institute of  
Medical Sciences, New Delhi, India (*Temporary Adviser*)

Dr M.N.G. Dukes, Regional Officer for Pharmaceuticals and Drug Utilization,  
WHO Regional Office for Europe, Copenhagen, Denmark

Dr J.F. Dunne, Chief, Pharmaceuticals, WHO, Geneva, Switzerland (*Secretary*)

Professor A. Wasunna, Chairman, Department of Surgery, University of Nairobi,  
Faculty of Medicine, Kenyatta National Hospital, Nairobi, Kenya (*Tempo-  
rary Adviser*)



# THE USE OF ESSENTIAL DRUGS

## Report of a WHO Expert Committee

The WHO Expert Committee on the Use of Essential Drugs met in Geneva from 29 November to 3 December 1982. The meeting was opened on behalf of the Director-General by Dr B. Sankaran, Director, Division of Diagnostic, Therapeutic, and Rehabilitative Technology.

### 1. INTRODUCTION

In a report<sup>1</sup> to the Twenty-eighth World Health Assembly in 1975, the Director-General reviewed the main drug problems facing the developing countries and outlined possible new drug policies. The Director-General also referred to the experience gained in some countries where schemes of basic or essential drugs had been implemented. Such schemes were intended to extend the accessibility of the most necessary drugs to those populations whose basic health needs could not be met by the existing supply system. He pointed out that the selection of these essential drugs would depend on the health needs and on the structure and development of health services of each country, and that lists of essential drugs should be drawn up locally, and periodically updated, with the advice of experts in public health, medicine, pharmacology, pharmacy and drug management. He also considered that adequate information on the properties, indications and use of the drugs listed should be provided. By resolution WHA28.66, the Health Assembly requested the Director-General to implement the proposals contained in his report and, in particular, to advise Member States on the selection and procurement, at reasonable cost, of essential drugs of established quality corresponding to their national health needs.

Following wide consultation, an initial model list of essential drugs was issued in the first report of the Expert Committee on the

---

<sup>1</sup> WHO Official Records, No. 226, 1975, Annex 13, pp. 96-110.

Selection of Essential Drugs.<sup>1</sup> This was subsequently revised and updated in a second report.<sup>2</sup>

In undertaking a further review of the list the present Expert Committee has throughout been guided by the following statement contained in the previous reports:

*"Because of the great differences between countries, the preparation of a drug list of uniform, general applicability and acceptability is not feasible or possible. Therefore, each country has the direct responsibility of evaluating and adopting a list of essential drugs, according to its own policy in the field of health.*

*"The list of essential drugs based on the guidelines put forward in this report is a model which can furnish a basis for countries to identify their own-priorities and to make their own selection."*

## **2. GUIDELINES FOR ESTABLISHING A NATIONAL PROGRAMME FOR ESSENTIAL DRUGS**

Since the first report on the selection of essential drugs was published in 1977, the concept of essential drugs has become widely recognized as useful. It has provided a rational basis not only for drug procurement at national level but also for establishing drug requirements at various levels within the health care system. In fact, many developing countries have already selected essential drugs according to their needs and the related programmes are, in some cases, in an advanced stage of implementation.

In order to ensure that an essential drugs programme is adequately instituted at national level, several steps are advised:

(1) The establishment of a list of essential drugs, based on the recommendations of a local committee, is the starting-point of the programme. The committee should include individuals competent in the fields of medicine, pharmacology and pharmacy, as well as peripheral health workers. Where individuals with adequate training are not available within the country, assistance from WHO could be sought.

(2) The international nonproprietary (generic) names for drugs or pharmaceutical substances<sup>3</sup> should be used whenever available, and

<sup>1</sup> WHO Technical Report Series, No. 615, 1977.

<sup>2</sup> WHO Technical Report Series, No. 641, 1979.

<sup>3</sup> See *International Nonproprietary Names (INN) for Pharmaceutical Substances: Cumulative List No. 6*, Geneva, World Health Organization, 1982. Further lists of proposed and recommended INN are issued periodically as supplements to the *WHO Chronicle*.

prescribers should be provided with a cross-index of nonproprietary and proprietary names.

(3) Concise, accurate, and comprehensive drug information should be prepared to accompany the list of essential drugs.

(4) Quality, including stability and bioavailability, should be assured through testing or regulation, as discussed in section 7.

(5) The success of the entire essential drugs programme is dependent upon the efficient administration of supply, storage and distribution at every point from the manufacturer to the end user. Government intervention may be necessary to ensure the availability of some drugs in the formulations listed, and special arrangements may need to be instituted for the storage and distribution of drugs that have a short shelf-life or require refrigeration.

(6) Efficient management of stocks is necessary to eliminate waste and to ensure continuity of supplies. Procurement policy should be based upon detailed records of turnover. In some instances, drug utilization studies may contribute to a better understanding of true requirements.

(7) Research, both clinical and pharmaceutical, is sometimes required to settle the choice of a particular drug product under local conditions (see section 8).

### **3. CRITERIA FOR THE SELECTION OF ESSENTIAL DRUGS**

Essential drugs are those that satisfy the health care needs of the majority of the population; they should therefore be available at all times in adequate amounts and in the appropriate dosage forms.

The choice of such drugs depends on many factors, such as the pattern of prevalent diseases; the treatment facilities; the training and experience of the available personnel; the financial resources; and genetic, demographic, and environmental factors.

Only those drugs should be selected for which sound and adequate data on efficacy and safety are available from adequate clinical studies and for which evidence of performance in general use in a variety of medical settings has been obtained.

Each selected drug must be available in a form in which adequate quality, including bioavailability, can be assured; its stability under the anticipated conditions of storage and use must be established.

Where two or more drugs appear to be approximately similar in the above respects, the choice between them should be made on the basis of a careful evaluation of their relative efficacy, safety, quality, price, and availability. In cost comparisons between drugs the cost of the total treatment, and not only the unit cost of the drug, must be considered. In some cases the choice may also be influenced by other factors, such as comparative pharmacokinetic properties, or by local considerations such as the availability of facilities for manufacture or storage.

In the great majority of cases essential drugs should be formulated as single compounds. Fixed-ratio combination products are acceptable only when the dosage of each ingredient meets the requirements of a defined population group and when the combination provides a proven advantage over single compounds administered separately in therapeutic effect, safety or compliance.

#### **4. GUIDELINES FOR THE SELECTION OF PHARMACEUTICAL DOSAGE FORMS**

The purpose of selecting dosage forms and strengths for the drugs in the model list is to provide guidance to countries wishing to standardize or minimize the number of preparations in their own drug lists. As a general rule, pharmaceutical forms are selected on the basis of their general utility and their wide availability internationally. In many instances, a choice of preparations is provided, particularly in relation to solid dosage forms. Tablets are usually less expensive than capsules, but, while the cost factor should be taken into account, the selection should also be based on a consideration of pharmacokinetics, bioavailability, stability under ambient climatic conditions, availability of excipients, and established local preference.

In a few instances, exemplified by acetylsalicylic acid and paracetamol, a range of dosage strengths is provided from which suitable strengths should be selected on the basis of local availability and need. When precise dosage is not mandatory, the use of scored tablets is recommended as a simple method of making dosage more flexible if so required and, in some instances, to provide a convenient paediatric dose. Specific paediatric dosages and formulations are included in the list only when indicated by special circumstances. In

most instances, dosage is specified in terms of a selected salt or ester but, in other instances—e.g., that of chloroquine—it is calculated, in accordance with common practice, in terms of the active moiety.

## **5. UPDATING OF LISTS OF ESSENTIAL DRUGS**

Experience with the original and the revised model lists, and with regional and national lists of essential drugs, has confirmed the need for regular review and updating. Revision is rendered necessary not only by advances in drug therapy but also in order to meet the needs of practice in the light of experience. Frequent and extensive changes are clearly undesirable since they result in disruption of channels of procurement and distribution and may have implications for the training of health personnel. For this reason a number of drugs have been retained on the model list that have been largely superseded in countries where there is a wider choice of new medications, but that are still used widely and successfully elsewhere.

The present Expert Committee introduced changes only where definite advantages were considered to accrue and, in some cases (e.g., the use of timolol in glaucoma, and cephalosporins), it was considered premature to include drugs of considerable promise on the list. However, several important modifications have been made, particularly in relation to anti-infective drugs, and these are listed in section 11. The Expert Committee noted, as on previous occasions, that as far as is possible individual sections of the list should be reviewed by subsequent committees on the basis of specialist advice and documentation.

## **6. PROVISION OF INFORMATION ON ESSENTIAL DRUGS**

Concise, accurate and comprehensive information on the use of essential drugs should be available to all prescribers in a format that is appropriate to their responsibilities and level of training. In order to assist countries in this task the Expert Committee advised that drug information sheets for doctors, now prepared in draft form in response to a recommendation in the first report of the Expert Committee on the Selection of Essential Drugs, be subjected to

broad consultation and subsequently issued together with general advice on therapeutic matters in a WHO model formulary. These sheets are organized in the following format:

1. International Nonproprietary Name (INN) of each active substance, and recommended dosage form.
2. Pharmacological information: brief description of pharmacological effects and mechanism of action.
3. Clinical information:
  - 3.1 Indications: whenever it is thought appropriate, simple diagnostic criteria should be provided.
  - 3.2 Dosage regimen and relevant pharmacokinetic data:
    - 3.2.1 Average dosage and range for adults and children
    - 3.2.2 Dosing interval
    - 3.2.3 Average duration of treatment
    - 3.2.4 Special situations, e.g., renal, hepatic, cardiac or nutritional insufficiencies which require either upward or downward dosage adjustments
  - 3.3 Contraindications
  - 3.4 Precautions (reference to pregnancy, lactation, etc.)
  - 3.5 Adverse effects (quantitate by category, if possible)
  - 3.6 Drug interactions (to be mentioned only if clinically relevant; drugs used for self-medication should be included)
  - 3.7 Overdosage:
    - 3.7.1 Brief clinical description of symptoms
    - 3.7.2 Non-drug treatment and supportive therapy
    - 3.7.3 Specific antidotes
4. Pharmaceutical information

It was recognized that this formulary, once produced, will need to be updated promptly as occasion demands if it is to be of optimal value and an appropriate consultative procedure will need to be established to permit this.

The Committee also recognized the urgent need for information appropriate to other categories of health personnel and particularly to community health workers. This is further discussed in section 12.

## 7. QUALITY ASSURANCE

Quality assurance of drugs, as embodied in good manufacturing practice and subsequent monitoring of quality through to utilization, is a critical element in any essential drugs programme. All aspects of these procedures have been dealt with *in extenso* in the

twenty-sixth, twenty-seventh and twenty-eighth reports of the WHO Expert Committee on Specifications for Pharmaceutical Preparation.<sup>1</sup>

WHO has set up a "Certification scheme on the quality of pharmaceutical products moving in international commerce" (in accordance with resolution WHA 28.65)<sup>2</sup> which provides valuable safeguards in relation to imported products, particularly for countries lacking adequate laboratory facilities for drug analyses.

Bioavailability is a specific problem that is of particular importance with products with low solubility or a narrow therapeutic index. In addition, unsatisfactory formulation can result in therapeutic failure due to lack of absorption. This has been discussed in the report of the WHO Scientific Group on the Bioavailability of Drugs.<sup>3</sup>

## 8. RESEARCH AND DEVELOPMENT

The establishment of essential-drugs programmes in developing countries will improve health care and reduce its costs. Further efforts, however, are required to upgrade medical care and to promote self-reliance through research and development in the clinical, pharmaceutical and administrative sectors.

In the clinical field, new drugs need to be evaluated; the benefits and safety of some traditionally used herbal remedies investigated; the effects of genetic, nutritional, and environmental factors on the therapeutic response established; and the value of non-medicinal forms of treatment explored. Dose-response studies should be conducted where there appear to be differences in therapeutic response or incidence of adverse reactions in specific populations.

In the pharmaceutical field, local quality control facilities need to be developed, and dosage forms that improve the stability of drugs under extreme climatic conditions, or reduce the problem of non-compliance, are required.

Operational research is indispensable to improve procurement procedures, and to evaluate and improve distribution systems, having particular regard to less-commonly required drugs.

---

<sup>1</sup> WHO Technical Report Series, No. 614, 1977; No. 645, 1980; No. 681, 1982.

<sup>2</sup> WHO Official Records, No. 226, 1975, p. 35 and Annex 12, p. 88. Republished as supplement to *WHO Chronicle*, Vol. 31, No. 12, 1977.

<sup>3</sup> WHO Technical Report Series, No. 536, 1974.

## 9. SPECIALIZED APPLICATIONS OF THE ESSENTIAL-DRUGS CONCEPT

Although the concept of essential drugs is directed primarily to the needs of developing countries, it has value in other contexts. The provision of drugs on ships provides an obvious example. It is particularly noteworthy that the model list was used to prepare the list of standard drugs and clinic equipment for 10 000 persons for 3 months developed jointly by WHO and the Office of the United Nations High Commissioner for Refugees as part of an emergency health kit.<sup>1</sup> This kit is also being adopted by other organizations involved in meeting emergency health care needs.

## 10. REVISED MODEL LIST OF ESSENTIAL DRUGS Explanatory Notes<sup>2</sup>

In many instances various drugs could serve as alternatives to those on the list. In these cases, the substance selected provides an *example of a therapeutic group* and is distinguished by being preceded by a square symbol (□). It is imperative that this should be understood when drugs are selected at national level, since the choice is then influenced by the comparative cost and availability of equivalent products. Examples of acceptable substitutions include:

- Codeine: other drugs for the symptomatic treatment of diarrhoea such as diphenoxylate or loperamide or, when indicated for cough relief, noscapine or dextromethorphan.
- Hydrochlorothiazide: any other thiazide-type diuretic currently in broad clinical use.
- Hydralazine: any other peripheral vasodilator having an anti-hypertensive effect.
- Senna: any mild stimulant laxative (either synthetic or of plant origin).
- Sulfadimidine: any other short-acting systemically-active sulfonamide unlikely to cause crystalluria.

Numbers in parentheses following the drug names indicate:

---

<sup>1</sup> UNITED NATIONS HIGH COMMISSIONER FOR REFUGEES. *Handbook for emergencies*, Geneva, 1982-83, pp. 253-262. The list will be available separately from WHO in English, French, and Spanish.

<sup>2</sup> The numbers preceding the drug groups and subgroups in the model list (e.g., 11; 17.6.2) have been allocated, in accordance with the English alphabetical order, for convenience in referring to the various categories; they have no formal significance.

- (1) Drugs subject to international control under the Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971);
- (2) Specific expertise, diagnostic precision or special equipment required for proper use;
- (3) Greater potency;
- (4) In renal insufficiency, contraindicated or dosage adjustments necessary;
- (5) To improve compliance;
- (6) Special pharmacokinetic properties for purpose;
- (7) Adverse effects diminish benefit/risk ratio;
- (8) Limited indications or narrow spectrum of activity;
- (9) For epidural anaesthesia.

Letters in parentheses following the drug names indicate the reasons for the inclusion of *complementary drugs*:

- (A) When drugs in the main list cannot be made available;
- (B) When drugs in the main list are known to be ineffective or inappropriate for a given individual;
- (C) For use in rare disorders or in exceptional circumstances.

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>1. Anaesthetics</b>		
1.1 <i>General anaesthetics and oxygen</i>		
ether, anaesthetic (2)		inhalation
halothane (2)		inhalation
nitrous oxide (2)		inhalation
oxygen		inhalation (medicinal gas)
thiopental (2)		powder for injection, 0.5 g, 1.0 g (sodium salt) in ampoule
1.2 <i>Local anaesthetics</i>		
<input type="checkbox"/> bupivacaine (2, 9)		injection, 0.25%, 0.5% (hydrochloride) in vial
<input type="checkbox"/> lidocaine		injection, 1%, 2% (hydrochloride) in vial injection, 1%, 2% + epinephrine 1:100 000 in vial topical forms, 2-4% (hydrochloride)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
------------------	---------------------------	---

## 2. Analgesics, Antipyretics, Nonsteroidal Antiinflammatory Drugs and Drugs Used to Treat Gout

### 2.1 Non-opioids

acetylsalicylic acid		tablet, 100–500 mg suppository, 50–150 mg
allopurinol (4)		tablet, 100 mg
<input type="checkbox"/> ibuprofen		tablet, 200 mg
indometacin		capsule or tablet, 25 mg
paracetamol		tablet, 100–500 mg suppository, 100 mg
	colchicine (B, C) (7)	tablet, 0.5 mg
	probenecid (B, C)	tablet, 500 mg

### 2.2 Opioid analgesics and antagonists

morphine (1)		injection, 10 mg (sulfate or hydrochloride) in 1-ml ampoule
naloxone		injection, 0.4 mg (hydrochloride) in 1-ml ampoule
	<input type="checkbox"/> pethidine (A) (4, 10)	injection, 50 mg (hydrochloride) in 1-ml ampoule

### 3. Antiallergics

<input type="checkbox"/> chlorphenamine		tablet, 4 mg (maleate) injection, 10 mg in 1-ml ampoule
epinephrine		injection, 1 mg (as hydrochloride) in 1-ml ampoule
	cromoglicic acid (B) (2, 8)	oral inhalation (cartridge) 20 mg (sodium salt) per dose

## 4. Antidotes and Other Substances Used in Poisonings

### 4.1 General

charcoal, activated		powder
ipecacuanha		syrup, containing 0.14% ipecacuanha alkaloids calculated as emetine
<input type="checkbox"/> sodium sulfate		powder 5–15 g

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>4. Antidotes and Other Substances Used in Poisonings (continued)</b>		
4.2 <i>Specific</i>		
atropine		injection, 1 mg (sulfate) in 1-ml ampoule
deferoxamine		injection, 500 mg (mesilate) in vial
dimercaprol (2)		injection in oil, 50 mg/ml in 2-ml ampoule
naloxone		injection, 0.4 mg (hydrochloride) in 1-ml ampoule
protamine sulfate		injection 10 mg/ml in 5-ml ampoule
sodium calcium edetate (2)		injection, 200 mg/ml in 5-ml ampoule
sodium nitrite		injection, 30 mg/ml in 10-ml ampoule
sodium thiosulfate		injection, 250 mg/ml in 50-ml ampoule
	methylthioninium chloride (C) <sup>b</sup>	injection, 10 mg/ml in 10-ml ampoule
	penicillamine (C) (2)	capsule or tablet, 250 mg
<b>5. Antiepileptics</b>		
diazepam		injection, 5 mg/ml in 2-ml ampoule
ethosuximide		capsule or tablet, 250 mg
phenobarbital (1)		tablet, 50 mg, 100 mg syrup, 15 mg/5 ml
phenytoin		capsule or tablet, 25 mg, 100 mg (sodium salt) injection, 50 mg (sodium salt)/ml in 5-ml vial
	carbamazepine (B, C)	tablet, 200 mg
	valproic acid (B, C) (2, 4, 7)	tablet, 200 mg (sodium salt)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>b</sup> Synonym: methylene blue.

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>6. Antiinfective Drugs</b>		
<b>6.1. Anthelmintic drugs</b>		
□ mebendazole		tablet, 100 mg
niclosamide		tablet, 500 mg
piperazine		tablet, 500 mg (citrate or adipate) elixir or syrup (as citrate) equivalent to 500 mg hydrate/5 ml
pyrantel		chewable tablet, 250 mg (as embonate) oral suspension, 50 mg (as embonate)/ml
tiabendazole		chewable tablet, 500 mg
<b>6.2. Antiamoebic drugs</b>		
chloroquine		tablet, 200 mg (as phosphate or sulfate)
diloxanide		tablet, 500 mg (furoate)
□ metronidazole		tablet, 200–500 mg
	dehydroemetine (B) (1, 7)	injection, 60 mg (hydrochloride) in 1-ml ampoule
<b>6.3. Antibacterial drugs</b>		
<b>6.3.1. Penicillins</b>		
□ ampicillin (4)		capsule or tablet, 250 mg, 500 mg (anhydrous) powder for oral suspension, 125 mg (anhydrous)/5 ml powder for injection, 500 mg (as sodium salt) in vial
benzathine benzylpenicillin (5)		injection, 1.44 g benzylpenicillin (= 2.4 million IU)/5 ml in vial
benzylpenicillin		powder for injection, 0.6 g (= 1 million IU), 3.0 g (= 5 million IU) (as sodium or potassium salt) in vial
phenoxymethylpenicillin		tablet, 250 mg (as potassium salt) powder for oral suspension 250 mg (as potassium salt)/5 ml
procaine benzylpenicillin (7)		powder for injection, 1 g (= 1 million IU), 3 g (= 3 million IU)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>6. Antiinfective Drugs (continued)</b>		
6.3.2 <i>Other antibacterial drugs</i>		
<input type="checkbox"/> chloramphenicol (7)		capsule, 250 mg powder for injection, 1 g (as sodium succinate) in vial
<input type="checkbox"/> cloxacillin		capsule, 500 mg (as sodium salt) powder for injection, 500 mg (as sodium salt) in vial
erythromycin		capsule or tablet, 250 mg (as stearate or ethylsuccinate) oral suspension, 125 mg (as stearate or ethylsuccinate)/5 ml powder for injection, 500 mg (as lactobionate) in vial
<input type="checkbox"/> gentamicin (4)		injection, 10 mg, 40 mg (as sulfate)/ml in 2-ml vial
<input type="checkbox"/> metronidazole		tablet, 200–500 mg injection, 500 mg in 100 ml suppository, 500 mg, 1 g
salazosulfapyridine (2)		tablet, 500 mg
spectinomycin (8)		powder for injection, 2 g (as hydrochloride) in vial
<input type="checkbox"/> sulfadimidine (4)		tablet, 500 mg oral suspension, 500 mg/5 ml injection, 1 g (sodium salt) in 3-ml ampoule
<input type="checkbox"/> sulfamethoxazole + trimethoprim (4)		tablet, 100 mg + 20 mg, 400 mg + 80 mg
<input type="checkbox"/> tetracycline (4)		capsule or tablet, 250 mg (hydrochloride)
	<input type="checkbox"/> amikacin (B, C) (4)	injection, 250 mg (sulfate)/ml in 2-ml ampoule
	doxycycline (B) (5, 6)	capsule or tablet, 100 mg (as hydrochloride) injection, 100 mg (as hydrochloride)/5 ml in ampoule
	nitrofurantoin (A, B) (4, 7)	tablet, 100 mg

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>6. Antiinfective Drugs (continued)</b>		
<b>6.3.3 Antileprosy drugs</b>		
clofazimine		capsule, 100 mg
dapsone		tablet, 50 mg, 100 mg
rifampicin		capsule or tablet, 150 mg, 300 mg
	ethionamide (B)	tablet, 125 mg, 250 mg
	protionamide (B)	tablet, 125 mg
<b>6.3.4 Antituberculosis drugs</b>		
ethambutol		tablet, 100–500 mg (hydrochloride) <sup>c</sup>
isoniazid		tablet, 100–300 mg
pyrazinamide		tablet, 500 mg
rifampicin		capsule or tablet, 150 mg, 300 mg
streptomycin (4)		powder for injection, 1 g (as sulfate) in vial
thioacetazone + isoniazid		tablet, 50 mg + 100 mg, 150 mg + 300 mg
<b>6.4 Antifilarial drugs</b>		
diethylcarbamazine		tablet, 50 mg (citrate)
suramin sodium		powder for injection, 1 g in vial
<b>6.5 Antifungal drugs</b>		
amphotericin B		powder for injection, 50 mg in vial
griseofulvin (8)		tablet or capsule, 125 mg, 250 mg
nystatin		tablet, 500 000 IU
		pessary, 100 000 IU
	flucytosine (B)	capsule, 250 mg
	(4, 8)	infusion, 2.5 g in 250 ml
<b>6.6 Antileishmaniasis drugs</b>		
pentamidine (5)		powder for injection, 200 mg (isetionate or mesilate) in vial
sodium stibogluconate		injection, 33%, equivalent to 10% antimony, in 30-ml vial

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>c</sup> Two strengths are required for individual dosage adjustment.

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>6. Antiinfective Drugs (continued)</b>		
6.7 <i>Antimalarial drugs</i>		
□ chloroquine		tablet, 150 mg (as phosphate or sulfate) syrup, 50 mg (as phosphate or sulfate)/5 ml
primaquine		tablet, 7.5 mg, 15 mg (as phosphate)
quinine		tablet, 300 mg (as bisulfate or sulfate) injection, 300 mg (as dihydrochloride)/ml in 2-ml ampoule
	amodiaquine (B)	suspension, 150 mg (as hydrochloride)/5 ml
	sulfadoxine + pyrimethamine (B)	tablet, 500 mg + 25 mg
6.8 <i>Antischistosomal drugs</i>		
metrifonate		tablet, 100 mg
oxamniquine		capsule, 250 mg syrup, 250 mg/5 ml
praziquantel		tablet, 600 mg
6.9 <i>Antitrypanosomal drugs</i>		
melarsoprol (5)		injection, 3.6% solution
pentamidine (5)		powder for injection, 200 mg (isetionate or mesilate)
suramin sodium		powder for injection, 1 g in vial
	□ nifurtimox (C) (2, 8)	tablet, 30 mg, 120 mg, 250 mg
<b>7. Antimigraine Drugs</b>		
ergotamine (2, 7)		tablet, 2 mg (as tartrate)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>8. Antineoplastic and Immunosuppressive Drugs</b>		
azathioprine (2)		tablet, 50 mg powder for injection, 100 mg (as sodium salt) in vial
bleomycin (2)		powder for injection, 15 mg (as sulfate) in vial
busulfan (2)		tablet, 2 mg
calcium folinate (2) <sup>d</sup>		tablet, 15 mg injection, 3 mg/ml in 10-ml ampoule
chlorambucil (2)		tablet, 2 mg
cyclophosphamide (2)		tablet, 25 mg powder for injection, 500 mg in vial
cytarabine (2)		powder for injection, 100 mg in vial
□doxorubicin (2)		powder for injection, 10 mg, 50 mg (hydrochloride) in vial
fluorouracil (2)		injection, 50 mg/ml in 5-ml ampoule
methotrexate (2)		tablet, 2.5 mg (as sodium salt) injection, 50 mg (as sodium salt) in vial
procarbazine		capsule, 50 mg (as hydrochloride)
vincristine (2)		powder for injection, 1 mg, 5 mg (sulfate) in vial

#### 9. Antiparkinsonism Drugs

□biperiden		tablet, 2 mg (hydrochloride) injection, 5 mg (lactate) in 1-ml ampoule
levodopa + □carbidopa (5, 6)		tablet, 100 mg + 10 mg, 250 mg + 25 mg
	levodopa (A)	tablet or capsule, 250 mg

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>d</sup> Drug for "rescue therapy" with methotrexate.



<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
------------------	---------------------------	---

## 11. Blood Products and Blood Substitutes (continued)

### 11.3 Plasma substitute (continued)

factor IX complex (coagulation factors II, VII, IX, X, concentrate)  
(c) (2, 8) (dried)

All plasma fractions should comply with the WHO Requirements for the Collection, Processing and Quality Control of Human Blood and Blood Products<sup>f</sup>

## 12. Cardiovascular Drugs

### 12.1. Antianginal drugs

glyceryl trinitrate	tablet, (sublingual) 0.5 mg
<input type="checkbox"/> isosorbide dinitrate	tablet, (sublingual) 5 mg
<input type="checkbox"/> propranolol	tablet, 10 mg, 40 mg (hydrochloride)
<input type="checkbox"/> verapamil	injection, 1 mg (hydrochloride) in 1-ml ampoule tablet, 40 mg, 80 mg (hydrochloride) injection, 2.5 mg/ml (hydrochloride) in 2-ml ampoule

### 12.2 Antiarrhythmic drugs

isoprenaline	tablet, 10 mg; 15 mg (hydrochloride or sulfate)
lidocaine	injection, 20 mg (hydrochloride)/ml in 5-ml ampoule
<input type="checkbox"/> procainamide	tablet, 250 mg, 500 mg (hydrochloride) injection, 100 mg (hydrochloride)/ml in 10-ml ampoule
<input type="checkbox"/> propranolol	tablet, 10 mg, 40 mg (hydrochloride) injection, 1 mg (hydrochloride) in 1-ml ampoule
<input type="checkbox"/> quinidine (A, B)	tablet, 200 mg (sulfate)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>f</sup> WHO Technical Report Series, No. 626, Annex 1, 1978.

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>12. Cardiovascular Drugs (continued)</b>		
12.3 <i>Antihypertensive drugs</i>		
<input type="checkbox"/> hydralazine		tablet, 50 mg (hydrochloride)
<input type="checkbox"/> hydrochlorothiazide		tablet, 50 mg
<input type="checkbox"/> propranolol		tablet, 40 mg, 80 mg (hydrochloride)
<input type="checkbox"/> sodium nitroprusside (2, 8)		powder for preparing infusion, 50 g in ampoule
	methyldopa (A, B) (7)	tablet, 250 mg
	<input type="checkbox"/> reserpine (A) (7)	tablet, 0.1 mg, 0.25 mg injection, 1 mg in 1-ml ampoule
12.4 <i>Cardiac glycosides</i>		
digoxin (4)		tablet, 0.0625 mg, 0.25 mg oral solution, 0.05 mg/ml injection, 0.25 mg/ml in 2-ml ampoule
	digitoxin (B) (6)	tablet, 0.05 mg, 0.1 mg oral solution, 1 mg/ml injection, 0.2 mg in 1-ml ampoule
12.5 <i>Drugs used in shock or anaphylaxis</i>		
dopamine (2)		injection, 40 mg (hydrochloride)/ml in 5-ml vial
epinephrine		injection, 1 mg (as hydrochloride) in 1-ml ampoule
<b>13. Dermatological Drugs</b>		
13.1 <i>Antifungal drugs</i>		
benzoic acid + salicylic acid		ointment or cream, 6% + 3%
<input type="checkbox"/> miconazole		ointment or cream, 2% (nitrate)
nystatin		ointment or cream, 100 000 IU/g

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>13. Dermatological Drugs (continued)</b>		
13.2 <i>Antiinfective drugs</i>		
□neomycin + □bacitracin		ointment, 5 mg neomycin sulfate + 500 IU bacitracin zinc/g
13.3 <i>Antiinflammatory and antipruritic drugs</i>		
□betamethasone (3)		ointment or cream, 0.1% (as valerate)
□calamine lotion		lotion
□hydrocortisone		ointment or cream, 1% (acetate)
13.4 <i>Astringent drugs</i>		
aluminium acetate		solution, 13% for dilution
13.5 <i>Keratoplastic and keratolytic agents</i>		
coal tar		solution, topical 20%
salicylic acid		solution, topical 5%
13.6 <i>Scabicides and pediculicides</i>		
benzyl benzoate		lotion, 25%
lindane <sup>g</sup>		cream or lotion, 1%
<b>14. Diagnostic Agents</b>		
edrophonium (2, 8)		injection, 10 mg (chloride) in 1-ml ampoule
tuberculin, purified protein derivative (PPD)		injection
14.1 <i>Ophthalmic drugs</i>		
fluorescein		eye drops, 1% (sodium salt)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>g</sup> Previously identified as gamma benzene hexachloride.

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>14. Diagnostic Agents (continued)</b>		
14.2 <i>Radiocontrast media</i>		
<input type="checkbox"/> adipiodone meglumine		injection, 25% in 20-ml vial
<input type="checkbox"/> barium sulfate		powder
<input type="checkbox"/> iopanoic acid		tablet, 500 mg
<input type="checkbox"/> meglumine amidotrizoate		injection, 60% in 20-ml ampoule
<input type="checkbox"/> sodium amidotrizoate		injection, 50% in 20-ml ampoule
<b>15. Disinfectants</b>		
<input type="checkbox"/> chlorhexidine		solution, 5% (gluconate) for dilution
<input type="checkbox"/> iodine		solution, 2.5%
<b>16. Diuretics</b>		
<input type="checkbox"/> amiloride		tablet, 5 mg (hydrochloride)
<input type="checkbox"/> furosemide		tablet, 40 mg injection, 10 mg/ml in 2-ml ampoule
<input type="checkbox"/> hydrochlorothiazide		tablet, 50 mg
mannitol		injectable solution, 10%, 20%
spironolactone		tablet, 25 mg
	chlortalidone (B) (6)	tablet, 50 mg
<b>17. Gastrointestinal Drugs</b>		
17.1 <i>Antacids and other antiulcer drugs</i>		
aluminium hydroxide		tablet, 500 mg oral suspension, 320 mg/5 ml
cimetidine		tablet, 200 mg injection, 200 mg in 2-ml ampoule
magnesium hydroxide		oral suspension, equivalent to 550 mg magnesium oxide/10 ml
	calcium carbonate (A, B)	tablet, 600 mg

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>17. Gastrointestinal Drugs (continued)</b>		
17.2 <i>Antiemetic drugs</i>		
<input type="checkbox"/> promethazine		tablet, 10 mg, 25 mg (hydrochloride) elixir or syrup, 5 mg (hydrochloride)/5 ml injection, 25 mg (hydrochloride)/ml in 2-ml ampoule
	metoclopramide (c)	tablet, 10 mg (as hydrochloride)
17.3 <i>Antihaemorrhoidal drugs</i>		
<input type="checkbox"/> local anaesthetic, astringent and anti-inflammatory drug		ointment or suppository
17.4 <i>Antispasmodic drugs</i>		
<input type="checkbox"/> atropine		tablet, 1 mg (sulfate) injection, 1 mg (sulfate) in 1-ml ampoule
17.5 <i>Cathartic drugs</i>		
<input type="checkbox"/> senna		tablet, 7.5 mg (sennosides)
17.6 <i>Diarrhoea, drugs used in</i>		
17.6.1 <i>Antidiarrhoeal (symptomatic) drugs</i>		
<input type="checkbox"/> codeine (1)		tablet, 30 mg (phosphate)
17.6.2 <i>Replacement solution</i>		
oral rehydration salts (for glucose-salt solution)		
	<i>g/litre</i>	
sodium chloride	3.5	
sodium bicarbonate	2.5	
potassium chloride	1.5	
glucose	20.0	

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>18. Hormones</b>		
18.1 <i>Adrenal hormones and synthetic substitutes</i>		
<input type="checkbox"/> dexamethasone		tablet, 0.5 mg, 4 mg injection, 4 mg (sodium phosphate) in 1-ml ampoule
hydrocortisone		powder for injection, 100 mg (as sodium succinate) in vial
<input type="checkbox"/> prednisolone		tablet, 5 mg
	fludrocortisone (C)	tablet, 0.1 mg (acetate)
18.2 <i>Androgens</i>		
testosterone (2)		injection, 200 mg (enantate) in 1-ml ampoule injection, 25 mg (propionate) in 1-ml ampoule
18.3 <i>Estrogens</i>		
<input type="checkbox"/> ethinylestradiol		tablet, 0.05 mg
18.4 <i>Insulins and other antidiabetic agents</i>		
<input type="checkbox"/> compound insulin zinc suspension		injection, 40 IU/ml in 10-ml vial, 80 IU/ml in 10-ml vial
insulin injection		injection, 40 IU/ml in 10-ml vial, 80 IU/ml in 10-ml vial
<input type="checkbox"/> glibenclamide		tablet, 5 mg
18.5 <i>Oral contraceptives</i>		
<input type="checkbox"/> ethinylestradiol + <input type="checkbox"/> levonorgestrel		tablet, 0.03 mg + 0.15 mg, 0.05 mg + 0.25 mg
<input type="checkbox"/> ethinylestradiol + <input type="checkbox"/> norethisterone		tablet, 0.05 mg + 1.0 mg
	<input type="checkbox"/> norethisterone (B)	tablet, 0.35 mg
18.6 <i>Ovulation inducers</i>		
	clomifene (C) (2, 8)	tablet, 50 mg (citrate)

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".



<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>19. Immunologicals (continued)</b>		
19.2 Vaccines		
19.2.1 For universal immunization		
BCG vaccine (dried)		injection
diphtheria-pertussis-tetanus vaccine		injection
diphtheria-tetanus vaccine		injection
measles vaccine		injection
poliomyelitis vaccine (live attenuated)		oral solution
tetanus vaccine		injection
19.2.2 For specific groups of individuals		
influenza vaccine		injection
meningococcal vaccine		injection
rabies vaccine		injection
typhoid vaccine		injection
yellow fever vaccine		injection

All vaccines should comply with the WHO Requirements for Biological Substances<sup>f</sup>

## 20. Muscle Relaxants (Peripherally Acting) and Cholinesterase Inhibitors

<input type="checkbox"/> neostigmine	tablet, 15 mg (bromide) injection, 0.5 mg (metilsulfate) in 1-ml ampoule
<input type="checkbox"/> gallamine (2)	injection, 40 mg (triethiodide)/ml in 2-ml ampoule

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<sup>f</sup> Dried BCG Vaccine (Revised 1978) (WHO Technical Report Series, No. 638, 1979); Diphtheria Toxoid, Pertussis Vaccine, Tetanus Toxoid, and Combined Vaccines (Revised 1978) (WHO Technical Report Series, No. 638, 1979), Addendum 1981 (WHO Technical Report Series, No. 673, 1982); Measles Vaccine (Live) and Measles Vaccine (Inactivated) (WHO Technical Report Series, No. 329, 1966); Poliomyelitis Vaccine (Oral) (Revised 1982) (WHO Technical Report Series, No. 687, 1983); Tetanus Toxoid (Revised 1978) (WHO Technical Report Series, No. 638, 1979); Influenza Vaccine (Inactivated) (Revised 1978) (WHO Technical Report Series, No. 638, 1979); Meningococcal Polysaccharide Vaccine (WHO Technical Report Series, No. 594, 1976), Addendum 1980 (WHO Technical Report Series, No. 658, 1981); Rabies Vaccine for Human Use (Revised 1980) (WHO Technical Report Series, No. 658, 1981); Typhoid Vaccine (WHO Technical Reports Series, No. 361, 1967); Yellow Fever Vaccine (Revised 1975) (WHO Technical Report Series, No. 594, 1976).

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
------------------	---------------------------	---

**20. Muscle Relaxants (Peripherally Acting) and Cholinesterase Inhibitors (continued)**

suxamethonium (2)		injection, 50 mg (chloride)/ml in 2-ml ampoule
	pyridostigmine (B) (2, 8)	tablet, 60 mg (bromide) injection, 1 ml (bromide) in 1-ml ampoule

**21. Ophthalmological Preparations**

21.1 *Antiinfective agents*

silver nitrate		solution (eye drops), 1%
sulfacetamide		eye ointment, 10% (sodium salt) solution (eye drops), 10% (sodium salt)
□ tetracycline		eye ointment, 1% (hydrochloride)

21.2 *Antiinflammatory agents*

hydrocortisone (2, 7)		eye ointment, 1% (acetate)
-----------------------	--	----------------------------

21.3 *Local anaesthetics*

□ tetracaine		solution (eye drops), 0.5% (hydrochloride)
--------------	--	--

21.4 *Miotics*

pilocarpine		solution (eye drops), 2%, 4% (hydrochloride or nitrate)
-------------	--	---

21.5 *Mydriatics*

□ homatropine		solution (eye drops), 2% (hydrobromide)
	epinephrine (A, B) (2)	solution (eye drops); 2% (as hydrochloride)

21.6 *Systemic preparations*

acetazolamide		tablet, 250 mg
---------------	--	----------------

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
------------------	---------------------------	---

## 22. Oxytocics

<input type="checkbox"/> ergometrine		tablet, 0.2 mg (maleate) injection, 0.2 mg (maleate) in 1-ml ampoule
oxytocin		injection, 10 IU in 1-ml ampoule

## 23. Peritoneal Dialysis Solution

intraperitoneal dialysis solution (of appropriate composition)		parenteral solution
--	--	---------------------

## 24. Psychotherapeutic Drugs

<input type="checkbox"/> amitriptyline		tablet, 25 mg (hydrochloride)
<input type="checkbox"/> chlorpromazine		tablet, 100 mg (hydrochloride) syrup, 25 mg (hydrochloride)/5 ml injection, 25 mg (hydrochloride)/ml in 2-ml ampoule
<input type="checkbox"/> diazepam		tablet, 5 mg
<input type="checkbox"/> fluphenazine (5)		injection, 25 mg (decanoate or enantate) in 1-ml ampoule
<input type="checkbox"/> haloperidol		tablet, 2 mg injection, 5 mg in 1-ml ampoule
lithium carbonate (2, 4, 7)		capsule or tablet, 300 mg

## 25. Respiratory Tract, Drugs Acting on the

### 25.1 *Antiasthmatic drugs*

<input type="checkbox"/> aminophylline		tablet, 200 mg injection, 25 mg/ml in 10-ml ampoule
epinephrine		injection, 1 mg (as hydrochloride) in 1-ml ampoule
<input type="checkbox"/> salbutamol		tablet, 4 mg (sulfate) oral inhalation (aerosol), 0.1 mg per dose syrup, 2 mg (sulfate)/5 ml

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
------------------	---------------------------	---

**25. Respiratory Tract, Drugs Acting on the (continued)**

25.1 *Antiasthmatic drugs (continued)*

beclometasone (B) (8)	oral inhalation (aerosol), 0.05 mg (dipropionate) per dose
cromoglicic acid (B) (2, 8)	oral inhalation (cartridge), 20 mg (sodium salt) per dose
ephedrine (A)	tablet, 30 mg (as hydrochloride) elixir, 15 mg (as hydrochloride)/5 ml injection, 50 mg (sulfate) in 1-ml ampoule

25.2 *Antitussives*

□codeine (1)	tablet, 10 mg (phosphate)
--------------	---------------------------

**26. Solutions Correcting Water, Electrolyte and Acid-base Disturbances**

26.1 *Oral*

oral rehydration salts (for glucose-salt solution)	[for composition, see 17.6.2: <i>Replacement solution</i> ]
potassium chloride	oral solution

26.2 *Parenteral*

□compound solution of sodium lactate	injectable solution
glucose	injectable solution, 5% isotonic, 50% hypertonic
glucose with sodium chloride	injectable solution, 4% glucose, 0.18% sodium chloride (Na <sup>+</sup> 30 mmol/l, Cl <sup>-</sup> 30 mmol/l)
potassium chloride	injectable solution
sodium bicarbonate	injectable solution, 1.4% isotonic (Na <sup>+</sup> 167 mmol/l, HCO <sub>3</sub> <sup>-</sup> 167 mmol/l)
sodium chloride	injectable solution, 0.9% isotonic (Na <sup>+</sup> 154 mmol/l, Cl <sup>-</sup> 154 mmol/l)
water for injection	in 2-ml, 5-ml, 10-ml ampoules

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

<i>Main list</i>	<i>Complementary list</i>	<i>Route of administration, dosage forms, and strengths<sup>a</sup></i>
<b>27. Vitamins and Minerals</b>		
ascorbic acid		tablet, 50 mg
□ ergocalciferol		capsule or tablet, 1.25 mg (50 000 IU) oral solution, 0.25 mg/ml (10 000 IU)
□ nicotinamide		tablet, 50 mg
pyridoxine		tablet, 25 mg (hydrochloride)
retinol		capsule or tablet, 7.5 mg (25 000 IU), 60 mg (200 000 IU) oral solution, 15 mg/ml (50 000 IU)
riboflavin		tablet, 5 mg
sodium fluoride (8)		tablet, 0.5 mg (as fluoride)
thiamine		tablet, 50 mg (hydrochloride)
	calcium gluconate (C) (2, 8)	injection, 100 mg/ml in 10-ml ampoule

<sup>a</sup> When the strength is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as".

/ For use in the treatment and prophylaxis of xerophthalmia.

ALPHABETICAL LIST OF ESSENTIAL DRUGS<sup>1</sup>

<i>Drug</i>	<i>Page</i>	<i>Drug</i>	<i>Page</i>
<b>A</b>		<b>B (continued)</b>	
acetazolamide	32	<input type="checkbox"/> bupivacaine	15
acetylsalicylic acid	16	busulfan	22
<input type="checkbox"/> adipiodone meglumine	27		
albumin, human normal	23		
allopurinol	16	<b>C</b>	
aluminium acetate	26	<input type="checkbox"/> calamine lotion	26
aluminium hydroxide	27	calcium carbonate	27
<input type="checkbox"/> amikacin	19	calcium folinate	22
<input type="checkbox"/> amiloride	27	calcium gluconate	35
<input type="checkbox"/> aminophylline	33	carbamazepine	17
<input type="checkbox"/> amitriptyline	33	<input type="checkbox"/> carbidopa + levodopa	22
amodiaquine	21	charcoal, activated	16
amphotericin B	20	chlorambucil	22
<input type="checkbox"/> ampicillin	18	<input type="checkbox"/> chloramphenicol	19
anti-D immunoglobulin (human)	30	<input type="checkbox"/> chlorhexidine	27
antihæmophilic fraction	23	chloroquine	18, 21
<input type="checkbox"/> antihæmorrhoidal preparation:		<input type="checkbox"/> chlorphenamine	16
local anaesthetic, astringent and		<input type="checkbox"/> chlorpromazine	33
antiinflammatory drug	28	chlortalidone	27
antirabies hyperimmune serum	30	cimetidine	27
antivenom sera	30	clofazimine	20
ascorbic acid	35	clomifene	29
<input type="checkbox"/> atropine	17, 28	<input type="checkbox"/> cloxacillin	19
azathioprine	22	coal tar	26
		<input type="checkbox"/> codeine	28, 34
<b>B</b>		colchicine	16
<input type="checkbox"/> bacitracin + <input type="checkbox"/> neomycin	26	cromoglicic acid	16, 34
<input type="checkbox"/> barium sulfate	27	cyclophosphamide	22
BCG vaccine (dried)	31	cytarabine	22
beclometasone	34		
benzathine benzylpenicillin	18	<b>D</b>	
benzoic acid + salicylic acid	25	dapsone	20
benzyl benzoate	26	deferoxamine	17
benzylpenicillin	18	dehydroemetine	18
<input type="checkbox"/> betamethasone	26	<input type="checkbox"/> dexamethasone	29
<input type="checkbox"/> biperiden	22	dextran 70	23
bleomycin	22		

<sup>1</sup> International nonproprietary names have been used whenever these are available; see footnote 3 on page 8.

<i>Drug</i>	<i>Page</i>	<i>Drug</i>	<i>Page</i>
<b>D (continued)</b>		<b>F (continued)</b>	
□ diazepam	17, 33	□ fluphenazine	33
diethylcarbamazine	20	folic acid	23
digitoxin	25	folic acid + ferrous salt	23
digoxin	25	□ furosemide	27
diloxanide	18		
dimercaprol	17		
diphtheria antitoxin	30	<b>G</b>	
diphtheria-pertussis-tetanus vaccine	31	□ gallamine	31
diphtheria-tetanus vaccine	31	□ gentamicin	19
dopamine	25	□ glibenclamide	29
□ doxorubicin	22	glucose	28, 34
doxycycline	19	glucose with sodium chloride	34
		glyceryl trinitrate	24
		griseofulvin	20
<b>E</b>			
edrophonium	26		
ephedrine	34	<b>H</b>	
epinephrine	16, 25, 32	□ haloperidol	33
□ ergocalciferol	35	halothane	15
□ ergometrine	33	heparin	23
ergotamine	21	□ homatropine	32
erythromycin	19	□ hydralazine	25
ethambutol	20	□ hydrochlorothiazide	25, 27
ether, anaesthetic	15	hydrocortisone	26, 29, 32
□ ethinylestradiol	29	□ hydroxocobalamin	23
□ ethinylestradiol + □ levonorgestrel	29		
□ ethinylestradiol + □ norethisterone	29	<b>I</b>	
ethionamide	20	□ ibuprofen	16
ethosuximide	17	immunoglobulin, human normal	30
		indometacin	16
<b>F</b>		influenza vaccine	31
factor IX complex (coagulation factors II, VII, IX, X, concentrate)	24	insulin injection	29
ferrous salt	23	□ insulin zinc suspension, compound	29
ferrous salt + folic acid	23	intra-peritoneal dialysis solution	33
flucytosine	20	□ iodine	27
fludrocortisone	29	□ iopanoic acid	27
fluorescein	26	□ ipecacuanha	16
fluorouracil	22	□ iron dextran	23
		isoniazid	20
		isoprenaline	24
		□ isosorbide dinitrate	24

<i>Drug</i>	<i>Page</i>	<i>Drug</i>	<i>Page</i>
<b>L</b>		<b>O (continued)</b>	
levodopa	22	oxygen	15
levodopa + □carbidopa	22	oxytocin	33
□levonorgestrel + □ethinylestradiol	29		
levothyroxine	30		
□lidocaine	15	<b>P</b>	
lindane	26	paracetamol	16
lithium carbonate	33	penicillamine	17
		pentamidine	20, 21
<b>M</b>		□pethidine	16
magnesium hydroxide	27	phenobarbital	17
mannitol	27	phenoxymethylpenicillin	18
measles vaccine	31	phenytoin	17
□mebendazole	18	phytomenadione	23
□meglumine amidotrizoate	27	pilocarpine	32
melarsoprol	21	piperazine	18
meningococcal vaccine	31	poliomyelitis vaccine (live attenuated)	31
methotrexate	22	potassium chloride, oral solution	28, 34
methylidopa	25	potassium chloride, parenteral	34
methylthioninium chloride	17	potassium iodide	30
metoclopramide	28	praziquantel	21
metrifonate	21	□prednisolone	29
□metronidazole	18, 19	primaquine	21
□miconazole	25	probenecid	16
morphine	16	□procainamide	24
		procaine benzylpenicillin	18
<b>N</b>		procarbazine	22
naloxone	17	□promethazine	28
□neomycin + □bacitracin	26	□propranolol	24, 25
□neostigmine	31	□propylthiouracil	30
niclosamide	13	protamine sulfate	17, 23
□nicotinamide	35	protionamide	20
□nifurtimox	21	pyrantel	18
nitrofurantoin	19	pyrazinamide	20
nitrous oxide	15	pyridostigmine	32
□norethisterone	29, 30	pyridoxine	35
□norethisterone + □ethinylestradiol	29	pyrimethamine + sulfadoxine	21
nystatin	20, 25		
		<b>Q</b>	
<b>O</b>		□quinidine	24
oral rehydration salts (for glucose-salt solution)	28, 34	quinine	21
oxamniquine	21		

<i>Drug</i>	<i>Page</i>	<i>Drug</i>	<i>Page</i>
<b>R</b>		<b>T</b>	
rabies vaccine	31	testosterone	29
□reserpine	25	tetanus antitoxin	30
retinol	35	tetanus vaccine	31
riboflavin	35	□tetracaine	32
rifampicin	20	□tetracycline	19, 32
		thiamine	35
		thiopental	15
<b>S</b>		thioacetazone + isoniazid	20
salazosulfapyridine	19	tiabendazole	18
□salbutamol	33	trimethoprim + □sulfamethoxazole	19
salicylic acid	26	tuberculin, purified protein derivative (PPD)	26
salicylic acid + benzoic acid	25	typhoid vaccine	31
□senna	28		
silver nitrate	32		
□sodium amidotrizoate	27	<b>V</b>	
sodium bicarbonate	34	valproic acid	17
sodium calcium edetate	17	□verapamil	24
sodium chloride	28, 34	vincristine	22
sodium chloride with glucose	34		
sodium fluoride	35		
□sodium lactate, compound solution	34		
sodium nitrite	17	<b>W</b>	
□sodium nitroprusside	25	□warfarin	23
sodium stibogluconate	20	water for injection	34
□sodium sulfate	16		
sodium thiosulfate	17		
spectinomycin	19		
spironolactone	27	<b>Y</b>	
streptomycin	20	yellow fever vaccine	31
sulfacetamide	32		
□sulfadimidine	19		
sulfadoxine + pyrimethamine	21		
□sulfamethoxazole + trimethoprim	19		
suramin sodium	20, 21		
suxamethonium	32		

## 11. CHANGES MADE IN REVISING THE MODEL LIST

Amendments to the individual entries in the model list are detailed below. In addition, some of the broad groups, shown in bold type in the list, have been revised (e.g., group 2 now comprises groups 2

and 3 of the previous list) and have been renumbered in consequence. The meanings of the typographical symbols used and of the numbers in parentheses following the drug names are not all the same as in the previous list (see Explanatory Notes in section 10). To avoid confusion, users are therefore urged to refer only to the present list and to cite the number of the report in which it is published (WHO Technical Report Series, No. 685).

*Group 3. Antiallergics:* An injectable formulation of □chlorphenamine is added.

*Group 4.1. Antidotes and Other Substances Used in Poisonings. General:* □Sodium sulfate is incorporated as an osmotic purgative.

*Group 6.1. Anthelmintic drugs:* Pyrantelembonate is added to the main list as both a chewable tablet and an oral suspension. □Mebendazole is qualified with a square symbol. Bephenium hydroxynaphthoate is deleted.

*Group 6.2. Antiamoebic drugs:* Chloroquine is added and diloxanide is transferred to the main list. Dehydroemetine replaces emetine in the complementary list, and note (A) is deleted. Paromomycin is deleted.

*Group 6.3.1. Penicillins:* Procaine benzylpenicillin is transferred to the main list.

*Group 6.3.2. Other antibacterial agents:* Spectinomycin injection and an injectable formulation and suppository of □metronidazole are added to the main list. The square symbol is added to □chloramphenicol, □gentamicin, □metronidazole, and □sulfamethoxazole + trimethoprim.

*Group 6.3.3. Antileprosy drugs:* A 50-mg tablet of dapsone is added. Clofazimine and rifampicin are transferred to the main list. Ethionamide and prothionamide are added as complementary drugs.

*Group 6.3.4. Antituberculosis drugs:* Pyrazinamide and thioacetazone + isoniazid are added to the main list.

*Group 6.5. Antifungal drugs:* A pessary formulation of nystatin and an injectable formulation of flucytosine are added.

*Group 6.7. Antimalarial drugs:* Amodiaquine suspension is added to the complementary list. Pyrimethamine as a single-component drug and the formate salt of quinine are deleted.

- Group 6.8. Antischistosomal drugs:* Praziquantel is added to the main list. Niridazole, antimony sodium tartrate, and sodium stibocaptate are deleted.
- Group 6.9. Antitrypanosomal drugs:* □Nifurtimox is transferred to the complementary list and a square symbol added.
- Group 9. Antiparkinsonism Drugs:* □Biperiden in both tablet and injectable forms replaces trihexyphenidyl in the main list. Levodopa + □carbidopa is transferred to the main list, while levodopa is moved to the complementary list.
- Group 10.1 Antianaemia drugs:* An oral solution of a ferrous salt is added to the main list. A combined tablet of ferrous salt + folic acid is added as a complementary drug.
- Group 10.2. Anticoagulants and antagonists:* A formulation of heparin containing 5000 IU/ml is added.
- Group 11.2. Plasma fractions for specific uses:* Fibrinogen and plasma protein injectable solution are deleted from the complementary list.
- Group 12.1. Antianginal drugs:* □Verapamil is added to the main list in tablet and injectable formulations.
- Group 12.2. Antiarrhythmic drugs:* Isoprenaline is added to the main list in a tablet formulation. A 250-mg tablet of procainamide is added.
- Group 12.3. Antihypertensive drugs:* An 80-mg tablet of □propranolol is added.
- Group 12.5. Drugs used in shock or anaphylaxis:* Isoprenaline hydrochloride is removed.
- Group 13.3. Antiinflammatory and antipruritic drugs:* □Calamine lotion is added.
- Group 16. Diuretics:* Spironolactone is added in a tablet formulation to the main list.
- Group 17.1. Antacids and other antiulcer agents:* Cimetidine is added to the main list in tablet and injectable formulations.
- Group 18.4. Insulins and other antidiabetic agents:* □Glibenclamide is added to the main list.
- Group 19.2.1. Vaccines for universal immunization:* Smallpox vaccine is deleted.

*Group 20. Muscle Relaxants (Peripherally Acting) and Cholinesterase Inhibitors:* □Gallamine is introduced to replace tubocurarine.

*Group 25.2. Antitussives:* A square symbol is added to □codeine.

*Group 26. Solutions Correcting Water, Electrolyte and Acid-base Disturbances:* A square symbol is added to □compound solution of sodium lactate.

*Group 27. Vitamins and Minerals:* Note (8) is added to sodium fluoride tablet 0.5 mg (as fluoride).

## 12. ESSENTIAL DRUGS AND PRIMARY HEALTH CARE

### 12.1 Factors affecting the selection of drugs for primary health care

The first report of the Expert Committee on the Selection of Essential Drugs recommended the compilation of a separate list of drugs appropriate for use in primary health care. After broad consultation, and having regard to situations in which a traditional healer or community health worker rather than a qualified doctor is the patients' first point of reference, the present Expert Committee has selected 22 substances or types of substance from the main list that might be considered for this purpose. They are listed in section 12.2. It cannot be emphasized too strongly that, in practice, the selection must be determined nationally since the training and responsibilities of these workers vary within wide limits. The following considerations, however, will inevitably influence the content of the list.

(1) *Existing systems of medicine.* The establishment of primary health care services should not result in abrupt disruption of prevailing cultural patterns in rural communities, but the work of traditional healers should be adapted and supplemented in such a way as to ensure that innovation is successfully integrated into existing systems of care.

(2) *The national health infrastructure.* The type of primary health care service that a country requires is dependent upon the proximity and nature of the first referral facilities. It is still not unusual in some countries for the nearest permanently manned health post to be one or more days' travelling time from isolated villages in its catchment area.

(3) *Training and supplies.* The numbers of trained personnel, the facilities placed at their disposal, and the supplies entrusted to them determine both the scope and the limitations of the primary health care system. Workers with one or more years' vocational training can obviously accomplish more than personnel who rely upon an intensive course of practical instruction lasting only a few weeks. But, whatever the circumstances, little can be accomplished unless continuity of essential supplies and information is assured.

(4) *The pattern of endemic disease.* The prevalence of major endemic infections and parasitic diseases may vary from region to region within a country in conformity with climatic, geographical, topographical, social, economic, and occupational factors. Careful planning and, in some cases, epidemiological surveys are required to ensure that the most effective drugs are provided, and to obtain full benefit from limited resources.

## 12.2 A model list of drugs for primary health care

acetylsalicylic acid  
activated charcoal  
an antacid  
an antihemorrhoidal drug  
atropine (antispasmodic)  
benzoic acid + salicylic acid  
benzyl benzoate  
calamine lotion  
chlorhexidine solution  
chloroquine  
chlorphenamine  
ephedrine (asthma)  
ergometrine (postpartum haemorrhage)  
iodine  
ipecacuanha  
iron/folic acid (nutritional supplement during pregnancy)  
lindane  
mebendazole  
oral rehydration salts  
paracetamol  
piperazine  
tetracycline eye ointment

The selected drugs, which should be available in the dosage forms specified in the main list, can be used effectively and safely by responsible individuals with little formal medical knowledge. The list is adapted to the needs of a malarious area (free from chloroquine resistance) where helminthic infections are also endemic, and the instructions for using the drugs can be based upon the recognition of a few basic clinical signs and symptoms.

Highly trained workers might use a wider range of drugs appropriate to their diagnostic skills with acceptable safety. However, where there is no scarcity of medical manpower, the provision of comprehensive emergency and domiciliary services involves the use of many potent drugs. Decisions regarding the availability of specific drugs to community health workers can be taken only when all the relevant factors that operate locally have been taken into account.

In ideal circumstances antibiotics, for instance, should be used only by individuals with advanced diagnostic skills and with access to appropriate microbiological facilities. However, the need for these drugs is as great in isolated rural communities as elsewhere and health administrators have a prime responsibility to ensure that, as far as possible, basic medical services are brought within the reach of the whole population.

### **12.3 Training material**

The Committee reviewed, and recommended for field testing, a series of draft information sheets relating to the above drugs, with a view to their eventual inclusion in a manual for teachers of community health workers.

## **13. GLOSSARY OF TERMS USED IN THE REPORT**

In the course of its work, the Expert Committee used certain terms with the meanings given below:

*Benefit/risk ratio* The ratio of benefit to risk in the use of a drug; a means of expressing a judgement concerning the role of the drug in the practice of medicine, based on efficacy and safety data along with consideration of misuse potential, severity and

	prognosis of the disease, etc. The concept may be applied to a single drug or in comparisons between two or more drugs used to treat the same condition.
<i>Bioavailability</i>	The rate and extent of absorption of a drug from a dosage form as determined by the curve of time versus its concentration in the systemic circulation or by measuring its excretion in urine.
<i>Compliance</i>	Faithful adherence by the patient to the prescriber's instructions.
<i>Dosage form</i>	The form of a completed pharmaceutical product, e.g., tablet, capsule, elixir, suppository.
<i>Drug</i>	Any substance used in a pharmaceutical product that is intended to modify or explore physiological systems or pathological states for the benefit of the recipient.
<i>Drug formulation</i>	The composition of a pharmaceutical product or the operations required to produce it.
<i>Drug utilization</i>	The marketing, distribution, prescription and use of drugs in a society, with special emphasis on the resulting medical, social and economic consequences.
<i>Efficacy</i>	The ability of a drug to produce the intended effect as determined by scientific methods.
<i>Excipient</i>	Any component of a finished dosage form other than the therapeutic ingredient or ingredients.
<i>Pharmaceutical product</i>	A dosage form containing one or more drugs along with other substances included during the manufacturing process.
<i>Pharmacokinetics</i>	The study of drug action, particularly with respect to the variation with time of drug concentrations in tissues and of absorption, distribution, metabolism and excretion of drugs and metabolites.

*Therapeutic  
equivalents*

Pharmaceutical products which, when administered to the same individuals in the same regimen, will result in essentially the same therapeutic or toxic effects.

**ACKNOWLEDGEMENTS**

The Expert Committee wishes to record its appreciation of the contributions made by Miss A. Wehrli, Pharmacist, Division of Diagnostic, Therapeutic and Rehabilitative Technology, WHO, Geneva, Switzerland.

**WORLD HEALTH ORGANIZATION  
TECHNICAL REPORT SERIES**

<i>Recent reports:</i>		
No.		Sw. fr.
648	(1980) <b>Evaluation of certain food additives</b> Twenty-third report of the Joint FAO/WHO Expert Committee on Food Additives (45 pages).....	3.—
649	(1980) <b>Environmental management for vector control</b> Fourth report of the WHO Expert Committee on Vector Biology and Control (75 pages).....	5.—
650	(1980) <b>Problems related to alcohol consumption</b> Report of a WHO Expert Committee (72 pages).....	5.—
651	(1980) <b>Vaccination against tuberculosis</b> Report of an ICMR/WHO Scientific Group (21 pages).....	2.—
652	(1980) <b>BCG vaccination policies</b> Report of a WHO Study Group (17 pages).....	2.—
653	(1980) <b>Evaluation of certain food additives</b> Twenty-fourth report of the Joint FAO/WHO Expert Committee on Food Additives (38 pages).....	3.—
654	(1980) <b>Peripheral neuropathies</b> Report of a WHO Study Group (138 pages).....	9.—
655	(1980) <b>Resistance of vectors of disease to pesticides</b> Fifth report of the WHO Expert Committee on Vector Biology and Control (82 pages).....	6.—
656	(1981) <b>Assessment of public health and social problems associated with the use of psychotropic drugs</b> Report of the WHO Expert Committee on Implementation of the Convention on Psychotropic Substances, 1971 (54 pages).....	4.—
657	(1981) <b>The effect of female sex hormones on fetal development and infant health</b> Report of a WHO Scientific Group (76 pages).....	5.—
658	(1981) <b>WHO Expert Committee on Biological Standardization</b> Thirty-first report (324 pages).....	21.—
659	(1981) <b>Wholesomeness of irradiated food</b> Report of a Joint FAO/IAEA/WHO Expert Committee (34 pages)...	3.—
660	(1981) <b>Nongonococcal urethritis and other selected sexually transmitted diseases of public health importance</b> Report of a WHO Scientific Group (142 pages).....	9.—
661	(1981) <b>Rapid laboratory techniques for the diagnosis of viral infections</b> Report of a WHO Scientific Group (60 pages).....	4.—
662	(1981) <b>Health effects of combined exposures in the work environment</b> Report of a WHO Expert Committee (76 pages).....	5.—
663	(1981) <b>Education and training in occupational health, safety and ergonomics</b> Eighth report of the Joint ILO/WHO Committee on Occupational Health (48 pages).....	3.—

No.		Sw. fr.
664	(1981) <b>Recommended health-based limits in occupational exposure to selected organic solvents</b> Report of a WHO Study Group (84 pages).....	6.—
665	(1981) <b>Neuronal aging and its implications in human neuronal pathology</b> Report of a WHO Study Group (88 pages).....	6.—
666	(1981) <b>Intestinal protozoan and helminthic infections</b> Report of a WHO Scientific Group (152 pages).....	10.—
667	(1981) <b>The role of the health sector in food and nutrition</b> Report of a WHO Expert Committee (92 pages).....	6.—
668	(1981) <b>Disability prevention and rehabilitation</b> Report of a WHO Expert Committee (40 pages).....	3.—
669	(1981) <b>Evaluation of certain food additives</b> Twenty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives (48 pages).....	3.—
670	(1981) <b>Research on the menopause</b> Report of a WHO Scientific Group (120 pages).....	8.—
671	(1982) <b>Tuberculosis control</b> Report of a Joint IUAT/WHO Study Group (26 pages).....	3.—
672	(1982) <b>Control of vitamin A deficiency and xerophthalmia</b> Report of a Joint WHO/UNICEF/USAID/Helen Keller International/IVACG Meeting (70 pages).....	7.—
673	(1982) <b>WHO Expert Committee on Biological Standardization</b> Thirty-second report (180 pages).....	13.—
674	(1982) <b>Treponemal infections</b> Report of a WHO Scientific Group (75 pages).....	6.—
675	(1982) <b>Chemotherapy of leprosy for control programmes</b> Report of a WHO Study Group (33 pages).....	4.—
676	(1982) <b>Interferon therapy</b> Report of a WHO Scientific Group (28 pages).....	3.—
677	(1982) <b>Recommended health-based limits in occupational exposure to pesticides</b> Report of a WHO Study Group (110 pages).....	8.—
678	(1982) <b>Prevention of coronary heart disease</b> Report of a WHO Expert Committee (53 pages).....	5.—
679	(1982) <b>Biological control of vectors of disease</b> Sixth report of the WHO Expert Committee on Vector Biology and Control (39 pages).....	4.—
680	(1982) <b>Malaria control and national health goals</b> Report of the Seventh Asian Malaria Conference (68 pages).....	6.—
681	(1982) <b>WHO Expert Committee on Specifications for Pharmaceutical Preparations</b> Twenty-eighth report (33 pages).....	4.—
682	(1982) <b>Bacterial and viral zoonoses</b> Report of a WHO Expert Committee with the participation of FAO (146 pages).....	11.—
683	(1982) <b>Evaluation of certain food additives and contaminants</b> Twenty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives (51 pages).....	5.—